<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503461</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/08</org_study_id>
    <nct_id>NCT03503461</nct_id>
  </id_info>
  <brief_title>Major Activation Of NCC in Graft Urinary Exosomes</brief_title>
  <acronym>MANGUE</acronym>
  <official_title>Evaluation of the Prevalence of an Hyperactivation of NCC Cotransporter Three Months After Kidney Transplantation in Recipients Treated by Calcineurin Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is common disorder after renal transplantation and is associated with mortality.&#xD;
      Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of&#xD;
      hypertension, included in a &quot;Gordon like&quot; syndrome. However, prevalence of NCC activation by&#xD;
      CNI is unknown. Our objective is to determine the prevalence of NCC activation three months&#xD;
      after transplantation in patient treated by CNI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is common disorder after renal transplantation and is associated with mortality.&#xD;
      Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of&#xD;
      hypertension, included in a &quot;Gordon like&quot; syndrome. Gordon syndrome is a rare genetic&#xD;
      disorder where NCC cotransporter is overactivated and cause hypertension, metabolic acidosis&#xD;
      and tendency to hyperkaliemia. Few studies evaluated NCC expression by exosomes techniques in&#xD;
      human kidney transplant, and mostly compared NCC expression in specific subpopulation (for&#xD;
      example with or without hypertension). Thus, prevalence of NCC activation by CNI is unknown.&#xD;
      To determine it, we will include prospective patients in Bordeaux and la Réunion who undergo&#xD;
      urine and blood tests three months after transplantation, and a control group with no&#xD;
      transplantation and no use of CNI. First, we will compare kidney recipients and control and&#xD;
      use immunoblot to quantify NCC expression in urinary exosomes to identify the population of&#xD;
      transplanted with a high activation. Then, we will analyze the relationship between NCC&#xD;
      activation and clinicobiological features of Gordon's syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NCC cotransporter expression</measure>
    <time_frame>Inclusion day</time_frame>
    <description>Dosage of NCC cotransporter expression in urinary exosomes samples in both groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated NCC cotransporter expression</measure>
    <time_frame>Inclusion day</time_frame>
    <description>Dosage of phosphorylated NCC cotransporter expression in urinary exosomes samples in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pendrine expression in kidney transplant group</measure>
    <time_frame>Inclusion day</time_frame>
    <description>Dosage of pendrine expression in urinary exosomes samples in kidney transplant group.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">67</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney transplants group</arm_group_label>
    <description>Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exosomes analysis</intervention_name>
    <description>Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Kidney transplants group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant group is a population of transplant subjects treated with anticalcineurin&#xD;
        since 3 months.&#xD;
&#xD;
        Control group is a population of subjects admitted to day hospitalization for renal&#xD;
        function tests or in conventional hospitalization, but without kidney transplant.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For kidney transplant group :&#xD;
&#xD;
          -  inclusion criteria:&#xD;
&#xD;
               -  Age≥18years&#xD;
&#xD;
               -  Recipients three months after kidney transplantation using calcineurin inhibitors&#xD;
&#xD;
               -  Glomerular Filtration Rate&gt;15ml.mn.m2 CKD-EPI&#xD;
&#xD;
               -  Renal ultrasound underwent before inclusion&#xD;
&#xD;
               -  No opposition at participating at the research&#xD;
&#xD;
          -  exclusion criteria:&#xD;
&#xD;
               -  Use of diuretic thiazides or aldosterone receptor antagonists in the month&#xD;
                  preceding inclusion&#xD;
&#xD;
               -  Graft artery stenosis with indication of interventional radiology or surgery&#xD;
&#xD;
        For control group :&#xD;
&#xD;
          -  Inclusion criteria&#xD;
&#xD;
               -  No previous transplantation&#xD;
&#xD;
               -  Age≥18years&#xD;
&#xD;
               -  No hypertension&#xD;
&#xD;
               -  No metabolic disorders (dysnatremia, dyskaliemia, acidosis or alkalosis)&#xD;
&#xD;
               -  No opposition at participating at the research&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  Use of diuretic thiazides or aldosterone receptor antagonists in the month&#xD;
                  preceding inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Pellegrin - Service Néphrologie, transplantation, dialyse et aphérèse</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Felix Guyon - Service d'Explorations Fonctionnelles Rénales</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>Réunion</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Réunion</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcineurin inhibitors</keyword>
  <keyword>hypertension</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>acidosis</keyword>
  <keyword>Gordon syndrome</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

